Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.68
Dollar change
-0.21
Percentage change
-5.40
%
Index- P/E- EPS (ttm)-0.35 Insider Own67.69% Shs Outstand13.32M Perf Week-3.66%
Market Cap68.12M Forward P/E- EPS next Y-0.20 Insider Trans0.90% Shs Float5.98M Perf Month0.82%
Income-3.85M PEG- EPS next Q-0.23 Inst Own7.25% Short Float1.32% Perf Quarter-47.73%
Sales79.18M P/S0.86 EPS this Y-252.38% Inst Trans7.08% Short Ratio0.39 Perf Half Y36.30%
Book/sh1.05 P/B3.49 EPS next Y72.97% ROA-4.23% Short Interest0.08M Perf Year168.61%
Cash/sh1.48 P/C2.48 EPS next 5Y- ROE-20.64% 52W Range1.02 - 8.11 Perf YTD-36.11%
Dividend Est.- P/FCF3.82 EPS past 5Y- ROI-11.01% 52W High-54.62% Beta0.83
Dividend TTM- Quick Ratio1.10 Sales past 5Y31.57% Gross Margin71.17% 52W Low260.78% ATR (14)0.45
Dividend Ex-Date- Current Ratio1.35 EPS Y/Y TTM85.81% Oper. Margin1.98% RSI (14)48.35 Volatility16.29% 11.01%
Employees80 Debt/Eq0.87 Sales Y/Y TTM7.48% Profit Margin-4.87% Recom1.00 Target Price8.25
Option/ShortNo / Yes LT Debt/Eq0.72 EPS Q/Q80.56% Payout- Rel Volume0.49 Prev Close3.89
Sales Surprise2.05% EPS Surprise-594.12% Sales Q/Q-4.44% EarningsMar 21 AMC Avg Volume201.56K Price3.68
SMA201.74% SMA50-12.47% SMA2003.58% Trades Volume99,036 Change-5.40%
Date Action Analyst Rating Change Price Target Change
Dec-07-21Initiated B. Riley Securities Buy $14
Mar-28-24 04:05PM
Mar-25-24 07:01PM
Mar-22-24 06:01AM
Mar-21-24 09:53PM
04:01PM
08:49AM Loading…
Mar-19-24 08:49AM
Mar-18-24 08:30AM
Mar-15-24 08:30AM
Mar-13-24 08:30AM
Mar-11-24 08:30AM
Feb-26-24 11:35AM
Jan-05-24 08:30AM
Jan-02-24 04:05PM
Dec-27-23 08:50AM
Dec-13-23 08:09AM
09:16AM Loading…
Dec-07-23 09:16AM
Dec-06-23 08:00AM
Nov-30-23 12:00PM
Nov-29-23 08:50AM
Nov-14-23 04:10PM
Nov-12-23 09:36AM
Nov-07-23 04:01PM
Nov-01-23 08:00AM
Oct-31-23 08:30AM
Oct-20-23 08:30AM
Sep-09-23 01:04AM
Sep-07-23 11:45AM
Sep-06-23 08:00AM
Aug-14-23 04:01PM
Aug-08-23 06:05PM
04:01PM Loading…
04:01PM
Aug-03-23 05:35PM
Aug-02-23 04:01PM
Jul-19-23 08:30AM
Jul-11-23 08:30AM
Jul-04-23 07:34AM
Jul-03-23 08:00AM
Jun-14-23 12:03PM
Jun-13-23 12:11PM
08:30AM
May-22-23 05:15PM
04:01PM
May-19-23 04:01PM
May-15-23 04:01PM
May-11-23 04:01PM
May-04-23 09:00AM
Apr-19-23 02:22PM
Apr-01-23 09:41PM
Mar-30-23 04:10PM
Mar-29-23 05:15PM
04:01PM
Mar-28-23 05:35PM
Mar-22-23 09:00AM
Mar-16-23 08:30AM
Mar-07-23 08:30AM
Jan-20-23 04:01PM
Jan-10-23 08:30AM
Dec-20-22 10:02AM
08:30AM
Dec-05-22 04:05PM
Nov-13-22 07:38AM
Nov-10-22 05:25PM
04:01PM
Nov-03-22 08:52AM
Oct-04-22 08:30AM
Aug-30-22 08:30AM
Aug-12-22 06:14AM
Aug-09-22 05:55PM
04:01PM
Aug-04-22 10:00AM
Aug-03-22 08:00AM
Jul-18-22 07:05AM
May-24-22 08:30AM
May-23-22 08:30AM
May-16-22 01:20PM
08:00AM
May-10-22 04:01PM
May-03-22 04:15PM
Apr-15-22 09:55AM
Apr-04-22 08:30AM
Apr-01-22 08:30AM
Mar-23-22 04:01PM
Mar-18-22 01:15PM
Mar-17-22 08:30AM
Mar-09-22 08:30AM
Feb-11-22 08:00AM
Jan-13-22 08:38AM
07:00AM
07:00AM
Dec-27-21 07:15AM
Dec-10-21 08:00AM
Dec-07-21 04:05PM
Nov-29-21 08:00AM
Nov-16-21 07:21PM
04:01PM
Nov-12-21 07:00AM
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENWALD LINDSAY A MDDirectorMar 25 '24Buy3.0410,00030,400144,245Mar 27 07:00 AM
Smith Justin AdamDirectorMar 22 '24Buy3.4730,000104,100134,717Mar 25 04:02 PM
ROSENWALD LINDSAY A MDDirectorMar 22 '24Buy3.4020,00068,000134,245Mar 25 04:01 PM
Maraoui ClaudePresident & CEOMar 22 '24Buy3.4810,00034,7902,163,430Mar 25 04:03 PM
Benesch JosephInterim CFOFeb 22 '24Sale3.752,4509,18860,710Feb 23 05:54 PM
Paley JeffreyDirectorNov 28 '23Sale5.221,7459,10970,727Nov 29 04:42 PM
Paley JeffreyDirectorNov 08 '23Sale3.76255959114,217Dec 08 05:01 PM
Paley JeffreyDirectorNov 07 '23Sale3.482,2457,813114,472Dec 08 05:01 PM
Smith Justin AdamDirectorOct 13 '23Buy2.9833,00098,340104,717Oct 17 04:01 PM
Paley JeffreyDirectorOct 06 '23Buy2.9815,00044,70072,472Oct 10 04:41 PM
Paley JeffreyDirectorSep 21 '23Buy2.9730,00089,10057,472Sep 25 04:01 PM
ROSENWALD LINDSAY A MDDirectorSep 06 '23Buy2.23100,000223,000114,245Sep 08 01:25 PM
Maraoui ClaudePresident & CEOSep 06 '23Buy2.5226,04465,6312,153,430Sep 08 01:26 PM
Maraoui ClaudePresident & CEOJul 24 '23Sale1.7620,76736,5502,127,386Jul 25 04:05 PM
Benesch JosephSee RemarksJul 24 '23Sale1.764,0727,16763,160Jul 25 04:05 PM
Maraoui ClaudePresident & CEOMay 17 '23Sale1.3424,37732,6652,148,153May 18 04:31 PM
Maraoui ClaudePresident & CEOMay 16 '23Sale1.2520,00025,0002,172,530May 18 04:31 PM